ReviewClinical advances in hematology & oncology : H&O2019
Next-generation sequencing for the general cancer patient.
Review in Clinical advances in hematology & oncology : H&O, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- ShinyEvents: harmonizing longitudinal data for real-world survival estimation.NPJ precision oncology · 2026Article
- The silent players: AtypicalOncology reports · 2025Review
- Comparative genomic analysis of multiple mammary tumors from a single dog: whole-genome sequencing study.Irish veterinary journal · 2025Article
- Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management.Diagnostics (Basel, Switzerland) · 2025Review
- Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Basket Trials: Past, Present, and Future.Annual review of cancer biology · 2024Article
- Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma.Frontiers in oncology · 2024Article
- Article
- Basic concepts of cancer genetics and receptor tyrosine kinase inhibition for pharmacists. A narrative review.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2023Review
- Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.Scientific reports · 2022Article
- Emerging genetic biomarkers in lung adenocarcinoma.SAGE open medicine · 2022Review
- Application of third-generation sequencing in cancer research.Medical review (2021) · 2021Article
- Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma.JAAD case reports · 2021Article
- Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTraOncotarget · 2021Article
- The Importance of Targeted Next-Generation Sequencing Usage in Cytogenetically Normal Myeloid Malignancies.Mediterranean journal of hematology and infectious diseases · 2021Article
- Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.PloS one · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Next-generation sequencing is a novel method of DNA sequencing that has become a cornerstone of precision oncology. This sequencing method detects differences in specific DNA sequences between a sample and a reference genome or matched normal DNA. In addition to single-nucleotide variants, other insertions, deletions, copy number changes, and fusions may be drivers of cancer growth, and thus represent therapeutic opportunities. As a result, genomic characterization has been increasingly used to guide treatment decisions, especially in patients with advanced disease. This review discusses the basic technologies involved in next-generation sequencing, the applications of this method, and limitations in the clinical realm.
Indexed as
Identifiers
31449513PMC6739831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.